IPSC Logo

Century Therapeutics, Inc. (IPSC) 

NASDAQ$0.6076+0.01 (1.68%)
Market Cap
$50.7M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
395 of 924
Rank in Industry
232 of 527

IPSC Insider Trading Activity

IPSC Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$7,65715
Sells
$122,3002195

Related Transactions

Quimi Daphnedirector1$7,6570$0$7,657
Carr DouglasSVP Finance & Operations0$05$2,710$-2,710
Farid AdrienneChief Operations Officer0$05$8,337$-8,337
Pfeiffenberger BrentPresident and CEO0$02$28,554$-28,554
Russotti GregorySee Remarks0$09$82,699$-82,699

About Century Therapeutics, Inc.

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, â€¦

Insider Activity of Century Therapeutics, Inc.

Over the last 12 months, insiders at Century Therapeutics, Inc. have bought $7,657 and sold $122,300 worth of Century Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Century Therapeutics, Inc. have bought $16M and sold $2.71M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Quimi Daphne (director) — $7,657.

The last purchase of 5,000 shares for transaction amount of $7,657 was made by Quimi Daphne (director) on 2024‑09‑12.

List of Insider Buy and Sell Transactions, Century Therapeutics, Inc.

2025-03-10SalePfeiffenberger BrentPresident and CEO
2,235
0.0027%
$0.61$1,375-2.17%
2025-03-10SaleCarr DouglasSVP Finance & Operations
1,240
0.0015%
$0.61$763-2.17%
2025-03-10SaleRussotti GregorySee Remarks
2,360
0.0028%
$0.61$1,451-2.17%
2025-03-10SaleFarid AdrienneChief Operations Officer
2,359
0.0028%
$0.61$1,451-2.17%
2025-02-18SalePfeiffenberger BrentPresident and CEO
34,712
0.0413%
$0.78$27,180-19.75%
2025-02-03SaleCarr DouglasSVP Finance & Operations
351
0.0004%
$0.78$274-9.35%
2025-02-03SaleFarid AdrienneChief Operations Officer
1,054
0.0012%
$0.78$822-9.35%
2024-11-04SaleCarr DouglasSVP Finance & Operations
283
0.0003%
$1.23$347-21.03%
2024-11-04SaleFarid AdrienneChief Operations Officer
1,033
0.0012%
$1.23$1,267-21.03%
2024-09-12PurchaseQuimi Daphnedirector
5,000
0.0059%
$1.53$7,657-20.78%
2024-08-05SaleCarr DouglasSVP Finance & Operations
289
0.0003%
$1.83$528-27.96%
2024-08-05SaleFarid AdrienneChief Operations Officer
1,073
0.0012%
$1.83$1,960-27.96%
2024-07-26SaleRussotti GregorySee Remarks
586
0.0007%
$2.50$1,465-45.00%
2024-07-24SaleRussotti GregorySee Remarks
1,600
0.002%
$2.52$4,029-41.60%
2024-07-23SaleRussotti GregorySee Remarks
200
0.0002%
$2.50$500-43.95%
2024-06-20SaleRussotti GregorySee Remarks
5,000
0.0052%
$2.84$14,179-45.72%
2024-06-05SaleRussotti GregorySee Remarks
5,000
0.006%
$3.00$14,989-50.67%
2024-05-20SaleRussotti GregorySee Remarks
5,000
0.006%
$3.00$14,978-49.17%
2024-05-06SaleRussotti GregorySee Remarks
5,000
0.0076%
$3.12$15,619-51.42%
2024-05-03SaleCarr DouglasSVP Finance & Operations
257
0.0004%
$3.11$798-49.17%
Total: 36
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Quimi Daphnedirector
5000
0.0059%
$2,981.5010
BAYER AKTIENGESELLSCHAFT10 percent owner
12675838
14.9077%
$7.56M10<0.0001%
Casdin Elidirector
3206380
3.7709%
$1.91M10<0.0001%
Versant Venture Capital VI, L.P.10 percent owner
714095
0.8398%
$425,814.8510<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$15,956,086
53
5.33%
$46.1M
$81,638,324
48
7.58%
$49.31M
$18,274,594
22
-26.07%
$49.68M
$1,087,418
21
1.95%
$45.39M
$160,539,875
21
-6.57%
$46.76M

IPSC Institutional Investors: Active Positions

Increased Positions44+75.86%6M+15.83%
Decreased Positions20-34.48%7M-16.72%
New Positions15New1MNew
Sold Out Positions10Sold Out2MSold Out
Total Postitions82+41.38%40M-0.89%

IPSC Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Bain Capital Life Sciences Investors, Llc$3,225.006.37%5.41M00%2024-12-31
Casdin Capital, Llc$3,094.006.11%5.19M+2M+61.58%2024-12-31
Vr Adviser, Llc$2,358.004.66%3.96M-1M-26.57%2024-12-31
Boxer Capital, Llc$2,324.004.59%3.9M-1M-20.43%2024-09-30
Blackrock, Inc.$1,810.003.57%3.04M+47,328+1.58%2024-12-31
Fmr Llc$1,510.002.98%2.53M+12,363+0.49%2024-12-31
Vanguard Group Inc$1,419.002.8%2.38M-93,508-3.78%2024-12-31
Dafna Capital Management Llc$1,016.002.01%1.7M00%2024-12-31
Millennium Management Llc$958.001.89%1.61M+1M+1,041.79%2024-12-31
Syncona Portfolio Ltd$723.001.43%1.21M00%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.